Clyde, D. F., Most, H., McCarthy, V. C. & Vanderberg, J. P. Immunization of man against sporozite-induced falciparum malaria. Am. J. Med Sci. 266, 169–177 (1973).
Pattanshetty, S. et al. A scoping review on malaria prevention and control intervention in fragile and conflict-affected states (FCAS): a need for renewed focus to enhance international cooperation. J. Epidemiol. Glob. Health 14, 4–12 (2024).
Suh, P. F. et al. Impact of insecticide resistance on malaria vector competence: a literature review. Malar. J. 22, 19 (2023).
Kagoro, F. M. et al. Mapping genetic markers of artemisinin resistance in plasmodium falciparum malaria in Asia: a systematic review and spatiotemporal analysis. Lancet Microbe 3, e184–e192 (2022).
Kahlon, A. et al. New malaria vaccine a boon to endemic regions – doubling efficacy rates, at lower cost. Travel Med Infect. Dis. 62, 102763 (2024).
Rts, S. Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31–45 (2015).
Asante, K. P. et al. Feasibility, safety, and impact of the RTS,S/AS01E malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi. Lancet 403, 1660–1670 (2024).
World Health Organisation. World malaria report 2023, published 30 November 2023, accessed 2 December 2024.
Datoo, M. S. et al. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet 403, 533–544 (2024).
Reece, W. H. et al. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat. Med. 10, 406–410 (2004).
Moita, D. & Prudencio, M. Whole-sporozoite malaria vaccines: where we are, where we are going. EMBO Mol. Med. 16, 2279–2289 (2024).
Goswami, D. et al. A replication-competent late liver stage-attenuated human malaria parasite. JCI Insight 5, e135589 (2020).
Roozen, G. V. T. et al. Single immunization with genetically attenuated Pf∆mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial. Nat. Med 31, 218–222 (2025).
Lamers, O. A. C. et al. Safety and efficacy of immunization with a late-liver-stage attenuated malaria parasite. N. Engl. J. Med 391, 1913–1923 (2024).
Mwakingwe-Omari, A. et al. Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity. Nature 595, 289–294 (2021).
Sulyok, Z. et al. Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial. Nat. Commun. 12, 2518 (2021).
Sklar, M. J. et al. A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naive adults. PLoS One 16, e0256980 (2021).
Plebanski, M. et al. Interleukin 10-mediated immunosuppression by a variant CD4 T cell epitope of Plasmodium falciparum. Immunity 10, 651–660 (1999).
Minigo, G. et al. Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS Pathog. 5, e1000402 (2009).
Hanboonkunupakarn, B. et al. A randomised trial of malaria vaccine R21/Matrix-M with and without antimalarial drugs in Thai adults. NPJ Vaccines 9, 124 (2024).
Silk, S. E. et al. Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial. Lancet Infect. Dis. 24, 1105–1117 (2024).
Natama, H. M. et al. Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children. Lancet Infect. Dis. https://doi.org/10.1016/s1473-3099(24)00752-7 (2024).
Seow, J. et al. Guiding the immune response to a conserved epitope in MSP2, an intrinsically disordered malaria vaccine candidate. Vaccines (Basel) 9, 855 (2021).
Duffy, P. E. Transmission-blocking vaccines: harnessing herd immunity for malaria elimination. Expert Rev. Vaccines 20, 185–198 (2021).
Good, M. F. & Yanow, S. K. Hiding in plain sight: an epitope-based strategy for a subunit malaria vaccine. Trends Parasitol. 39, 929–935 (2023).
Lyke, K. E. et al. Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial. Lancet Infect. Dis. 23, 578–588 (2023).
Mordmüller, B. et al. First-in-human, randomized, double-blind clinical trial of differentially adjuvanted PAMVAC, a vaccine candidate to prevent pregnancy-associated malaria. Clin. Infect. Dis. 69, 1509–1516 (2019).
Sirima, S. B. et al. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study. Lancet Infect. Dis. 20, 585–597 (2020).
Arévalo-Herrera, M. et al. Randomized clinical trial to assess the protective efficacy of a Plasmodium vivax CS synthetic vaccine. Nat. Commun. 13, 1603 (2022).
Woodberry, T. et al. Antibodies to plasmodium falciparum and plasmodium vivax merozoite surface protein 5 in Indonesia: species-specific and cross-reactive responses. J. Infect. Dis. 198, 134–142 (2008).
